BDMS: 1Q26 NP In Line; Earnings Revised Down On Weaker Revenue Growth Outlook

112 Views15 May 2026 07:04
Broker
We lower our 12M FV to Bt21.80, based on a required return of 4.7% (from Bt24.00/4.5%), while maintaining our Outperform rating given the still-attractive upside of 20%.
What is covered in the Full Insight:
  • Introduction to 1Q26 Results
  • Revenue and Profit Analysis
  • Impact of International Patient Trends
  • Operating Expenses and Profit Margins
  • Forward Outlook and Investment Rating
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 12-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • BDMS: 1Q26 NP In Line; Earnings Revised Down On Weaker Revenue Growth Outlook
    15 May 2026
x